FLT3 and acute myeloid leukemia: The safety and scientific validity of venetoclax in combination with FLT3 inhibitors gilteritinib (NCT03625505) and quizartinib (NCT03735875) are currently being tested in RR AML with FLT3 mutation (Table 2).